Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-73.46%
operating margin TTM
-67.21%
revenue TTM
271.02 Million
revenue per share TTM
2.6$
valuation ratios | |
|---|---|
| pe ratio | -2.10 |
| peg ratio | -0.17 |
| price to book ratio | -2.33 |
| price to sales ratio | 1.54 |
| enterprise value multiple | 0.29 |
| price fair value | -2.33 |
profitability ratios | |
|---|---|
| gross profit margin | 70.66% |
| operating profit margin | -67.21% |
| pretax profit margin | -72.59% |
| net profit margin | -73.46% |
| return on assets | -39.31% |
| return on equity | 133.65% |
| return on capital employed | -43.51% |
liquidity ratio | |
|---|---|
| current ratio | 4.12 |
| quick ratio | 3.05 |
| cash ratio | 0.73 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 429.12 |
| operating cycle | 500.44 |
| days of payables outstanding | 62.12 |
| cash conversion cycle | 438.32 |
| receivables turnover | 5.12 |
| payables turnover | 5.88 |
| inventory turnover | 0.85 |
debt and solvency ratios | |
|---|---|
| debt ratio | 1.05 |
| debt equity ratio | -2.97 |
| long term debt to capitalization | 1.63 |
| total debt to capitalization | 1.51 |
| interest coverage | -7.20 |
| cash flow to debt ratio | -0.39 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.87 |
| cash per share | 1.77 |
| operating cash flow per share | -1.83 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -0.39 |
| short term coverage ratios | -18.81 |
| capital expenditure coverage ratio | -47.46 |
Frequently Asked Questions
When was the last time Revance Therapeutics, Inc. (NASDAQ:RVNC) reported earnings?
Revance Therapeutics, Inc. (RVNC) published its most recent earnings results on 07-11-2024.
What is Revance Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Revance Therapeutics, Inc. (NASDAQ:RVNC)'s trailing twelve months ROE is 133.65%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Revance Therapeutics, Inc. (RVNC) currently has a ROA of -39.31%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RVNC's net profit margin stand at?
RVNC reported a profit margin of -73.46% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RVNC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.12 in the most recent quarter. The quick ratio stood at 3.05, with a Debt/Eq ratio of -2.97.